FDA committee proposes overhaul of perioperative lung cancer trials
The ODAC highlighted that perioperative trials should separately evaluate the effectiveness of treatments pre- and post-operation.
![](https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2024/07/shutterstock_2084674072-1-e1722011558860.jpg)
The ODAC highlighted that perioperative trials should separately evaluate the effectiveness of treatments pre- and post-operation.
The approval encompasses four variations of the Comirnaty JN.1 vaccine, following the International Recognition Procedure.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
How NVIDIA grew with the healthcare market instead of pushing into it
CytoReason secures $80m investment for AI expansion
Gene therapy: How Veristat cut trial database costs by 30%
Join the revolution of on-dose authentication